Skip to main content
SpringerLink
Log in

PI3K/AKT-Signalweg spielt Schlüsselrolle

Einblick in Gefitinib-Resistenz bei Lungenkrebs

  • neues aus der forschung
  • Published:
Info Onkologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  • Jeannot V et al. The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacety-lase-dependent mechanism. Int J Cancer. 2014;134(11):2560–71.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. http://www.springermedizin.de

    Doris Berger

Authors
  1. Doris Berger
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Berger, D. PI3K/AKT-Signalweg spielt Schlüsselrolle. Info Onkol. 17, 27 (2014). https://doi.org/10.1007/s15004-014-0932-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15004-014-0932-9

Search

Navigation